XW043K9 Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
Billable / valid for submission ICD10PCS Release FY2026-APR
Short description: Introduce Sulbac-Durlobac in Central Vein, Perc, New Tech 9
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| FY2026 | 2025-10-01 | 2026-03-31 | Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9 | yes |
| FY2026-APR | 2026-04-01 | current | Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9 | yes |
Related codes in XW0
- XW0 New Technology, Anatomical Regions, Introduction
- XW00X27 Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7
- XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
- XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
- XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
- XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013TB Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
- XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
- XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
- XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
- XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7